Cantor Fitzgerald Reiterates Overweight on Intellia Therapeutics, Maintains $65 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Rick Bienkowski has reiterated an Overweight rating on Intellia Therapeutics (NASDAQ:NTLA) and maintained a $65 price target.
June 04, 2024 | 5:28 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald analyst Rick Bienkowski has reiterated an Overweight rating on Intellia Therapeutics and maintained a $65 price target.
The reiteration of an Overweight rating and a maintained price target of $65 by a reputable analyst is likely to positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100